Transgene has a partnered with in-vitro diagnostics company Randox to combine their technologies and develop multifunctional oncolytic immunotherapies.

New oncolytic viruses (OVs) resulting from the current partnership will use Transgene’s latest viral platform Invir.IO, with one or more of Randox’s single-domain antibodies (SdAbs) will be vectorised.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Advanced immunotherapies will help combine the oncolytic effect of the viruses with properties of the vectorised SdAbs that will be locally expressed in the tumour microenvironment (TME) with the focus on treating patients with immunosuppressed solid tumours.

Randox Laboratories founder and managing director Dr Peter FitzGerald said: “We are looking forward to working with Transgene to generate OVs that will be able to express multiple functions directly into a tumour, enhancing their efficacy.

“This partnership will allow us to better leverage our SdAb capabilities and immuno-oncology expertise and add to our strategic collaborations across the world.”

“This partnership will allow us to better leverage our SdAb capabilities and immuno-oncology expertise and add to our strategic collaborations across the world.”

Under the deal, Transgene will create new anticancer oncolytic virus (OV) drugs by using its Vaccinia virus (TK-, RR-) strain, and its skill in molecular engineering and translational research.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new viral strain provides increased oncolytic properties and its large genome capacity allows multiple therapeutic payloads (anticancer weapons) to be delivered in a tumour, where the virus replicates.

In addition, Randox will offer expertise in antibody engineering and provide access to its collection of new and future immunotherapeutic SdAbs to be used as vectorised payloads.

The SdAbs will be able to modulate the patient’s immune response and generate a synergistic effect with Transgene’s oncolytic viral platform.